Form 4: Ligand Pharmaceuticals President & COO Matthew Korenberg Reports Stock Transactions

Matthew Korenberg, President & COO of Ligand Pharmaceuticals, reports exercising stock options and selling shares on September 20 and 23, 2024.

Summary

• On September 20, 2024, Matthew Korenberg, President & COO of Ligand Pharmaceuticals, exercised options to acquire 4,982 shares of common stock at $49.99 per share and sold 6,275 shares at a weighted average price of $104.1017.
• On September 23, 2024, Korenberg exercised options to acquire 395 shares at $49.99 per share and 9,377 shares at $52.84 per share.
• He also sold 2,481 shares at a weighted average price of $100.0517, 7,090 shares at $101.605, and 201 shares at $102.0541 on the same day.
• Following these transactions, Korenberg directly owns 50,777 shares of common stock.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company executives. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The information provided allows investors to track insider activity, which can be compared to similar filings from executives at comparable pharmaceutical companies to gauge sentiment and potential trends.

Stakeholder Impact

• Shareholders may be interested in these transactions as they provide insight into management's perspective on the company's stock value.
• The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates